Katherine E. Warren, MD, joins Dana-Farber/Boston Children’s as Clinical Director for Pediatric Neuro-Oncology
June 04, 2019
Katherine E. Warren, MD, has joined Dana-Farber/Boston
Children’s Cancer and Blood Disorders Center as the Clinical Director for
Warren is an internationally recognized expert in pediatric neuro-oncology.
Her work focuses on rational, pharmacokinetic-based drug development for
children with brain tumors, and she is a leading innovator in developing new
means of drug delivery.
“Dr. Warren is a world-renowned clinical researcher and mentor,
and we could not be more pleased that she is joining our program,” said David
Williams, MD, President of Dana-Farber/Boston Children’s. “We look forward to
her continuing and expanding her groundbreaking work here.”
Scott Armstrong, MD, PhD, Chairman of the Department of
Pediatric Oncology at Dana-Farber added, “We are quite fortunate to have Dr.
Warren join us as the leader of our neuro-oncology program. She brings a wealth
of experience and a vision that will help us expand our neuro-oncology clinical
program and cutting-edge clinical research.”
She is formerly the head of the Neuro-Oncology Section in the
Pediatric Oncology branch of the National Cancer Institute (NCI), where she has
overseen an extensive research program for children with brain tumors. Her
clinical trials have led the field in exploring new approaches for the
treatment of children with these diseases.
“My ultimate goal is to improve both survival and quality of
life for children with tumors of the central nervous system by using a rational
drug development approach. This means selecting and delivering agents specific for each patient’s tumor,
defining active drug concentrations pre-clinically, and determining the
feasibility of achieving effective
drug levels at the tumor site before going to the clinic. This will reduce the
number of patients receiving ineffective therapies or inadequate dosing while
preventing excessive dosing and accompanying toxicities that are typically observed
in clinical trials,” said Warren.
She continued, “Historically, clinical drug development for
children with CNS tumors has relied upon data passed down from adults; pre-clinical
studies were not done specifically for pediatric brain tumors because pediatric
brain tumor cell lines and animal models did not exist. Now that these are
available, we must utilize them in ways that can help optimize clinical trial
design. My aim is to replace the drug development paradigm that was developed
in the era of cytotoxic chemotherapy with a disease-, drug-, and patient-specific
paradigm that will allow for more efficient clinical trials while improving
outcome for each patient.”
Warren received her medical degree from Tufts University
School of Medicine and is a member of a number of professional societies and has
numerous publications to her credit.